The article says a provider weighs efficacy data against your metabolic profile, affordability, and whether you prefer an injection or an oral formulation
When data is available for retrospective studies, I think it's important to use it, said Wolff-Sagy
Trials like SARC045 are assessing pembrolizumab in sarcoma subtypes, including MPNST, particularly in tumors with mismatch repair deficiency or high tumor mutational burden
Hu, F.) 5383 (Oxford University Press, 2008)
By understanding the science behind these therapies and consulting with healthcare providers, individuals can make informed decisions about their health and performance goals
Protects Against Ischemia TB4 provides critical protective effects in low-blood-flow states